Related Experiment Video
Updated: Aug 15, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Antiplatelet and antithrombotic therapy in unstable angina
1Montreal Heart Institute, Quebec, Canada.
Insights
Aspirin and heparin significantly reduce coronary events in unstable angina patients. However, their high failure rates necessitate ongoing research for more effective antiplatelet and antithrombotic therapies.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Unstable angina presents a significant risk for coronary events.
- Current antiplatelet and antithrombotic therapies offer partial efficacy.
Purpose of the Study:
- To evaluate the efficacy of aspirin and heparin in managing unstable angina.
- To assess the benefits of these drugs across different disease phases and compare their effectiveness.
Main Methods:
- Analysis of 4 well-controlled clinical trials for aspirin efficacy.
- Review of 4 clinical trials examining the acute use of heparin.
Main Results:
- Aspirin demonstrated consistent reduction in coronary events across acute, subacute, and chronic phases.
- Heparin provided substantial acute benefits, outperforming aspirin in reducing event rates and refractory angina.
- Benefits of aspirin were observed across various doses and protocols.
Conclusions:
- Aspirin is effective in reducing coronary events in unstable angina.
- Heparin offers significant acute advantages over aspirin in managing unstable angina.
- Further research is crucial for developing superior antiplatelet and antithrombotic agents due to current treatment limitations.
Abstract:
In 4 well-controlled clinical trials, aspirin reduced the incidence of coronary events in unstable angina. The benefits were present during the acute, subacute and more chronic phases of the disease and were independent of the doses and of other protocol differences. This benefit of aspirin can be extended to some, but not all, other antiplatelet drugs. In 4 clinical trials, heparin used acutely added substantial benefit to the management of unstable angina, reducing the event rate and also the incidence of refractory angina more than aspirin. The long-term benefit of antithrombin therapy remains to be more thoroughly investigated. Despite these successes, the failure rate of aspirin and of heparin remains high, justifying a continuing search for more potent and safe antiplatelet and antithrombotic drugs.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Angina II: Classification
Angina IV: Management
Peripheral Artery Disease III: Interprofessional Care

